TY - JOUR
AU - Savontaus, Mikko
AB - 5,6 Juha Koskenvuo Mirva Söderström Background Doxorubicin is an effective anticancer drug. The major limita- 1,3,4 tion to its use is the induction of dose-dependent cardiomyopathy. No specific Kim Eerola 1,2,8 treatment exists for doxorubicin-induced cardiomyopathy and treatments used Mikko Savontaus for other forms of heart failure have only limited beneficial effects. The contraction–relaxation cycle of the heart is controlled by cytosolic calcium Turku Centre for Biotechnology, University of Turku, Turku, Finland concentrations, which, in turn, are critically regulated by the activity of the 2+ Department of Medical Biochemistry sarcoplasmic reticulum Ca ATPase (SERCA2a) pump. We hypothesized and Genetics, University of Turku, Turku, that SERCA2a gene transfer would ameliorate doxorubicin-induced Finland cardiomyopathy. Department of Pharmacology, Drug Methods Lentiviral vectors LV-SERCA2a-GFP and LV-GFP were constructed Development and Therapeutics, and in vitro gene transfer of LV-SERCA2a-GFP confirmed SERCA2a expression University of Turku, Turku, Finland 4 by western blot analysis. Heart failure was induced by giving a single intraper- Drug Research Doctoral Program, itoneal injection of doxorubicin. LV-SERCA2a-GFP, LV-GFP vectors and University of Turku, Turku, Finland 5 phosphate-buffered saline (PBS) were injected under echocardiographic con- Research Centre of Applied and trol to the anterior wall of the left ventricle. Preventive Cardiovascular Medicine, 
TI - Intramyocardial injection of SERCA2a‐expressing lentivirus improves myocardial function in doxorubicin‐induced heart failure
JO - Journal of Gene Medicine
DO - 10.1002/jgm.2885
DA - 2016-07-01
UR - https://www.deepdyve.com/lp/wiley/intramyocardial-injection-of-serca2a-expressing-lentivirus-improves-jsp8AJ6Ydf
SP - 124
EP - 133
VL - 18
IS - 7
DP - DeepDyve
ER -